A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This study will be conducted in accordance with the local regulation of New Drug Application.
Overall duration of this trial will be 3 years after approval of KFDA.
Each subject will participate around 7 weeks, which include the 2 weeks Amlodipine run-in
period, 4 weeks double blind period and 1 week safety follow up period